Therapiekosten von Orphan Drugs vor und nach Einführung des AMNOG

Durch das Wegfallen des ergänzenden Bundeszuschusses im Jahr 2023 entstand eine Debatte um mögliche Maßnahmen gegen die drohende Finanzierungslücke der GKV im Jahr 2023. So soll beispielsweise die Umsatzschwelle bei der Nutzenbewertung für Orphan Drugs auf 20 Millionen Euro gesenkt werden. Ziel der...

Full description

Bibliographic Details
Published in:	Monitor Versorgungsforschung
Main Authors:	Lukas Maag MSc, Dr. med. Ariane Höer, Fabian Berkemeier MSc, Dr. rer. nat. Gerrit Müller
Format:	Article
Language:	German
Published:	eRelation AG 2022-10-01
Subjects:	amnog orphan drugs pharmaceuticals health economics
Online Access:	https://www.monitor-versorgungsforschung.de/Abstracts/Kurzfassungen_2022/MVF-0522/MVF05-22_Maag-etal_%20OrphanDrugs

Similar Items

Preisregulierung durch Nutzenbewertung bei seltenen Erkrankungen
by: Lukas Maag MSc, et al.
Published: (2024-06-01)

Einsparungen durch AMNOG-Rabatte
by: Lukas Maag MSc, et al.
Published: (2023-10-01)

Abstimmungsverhalten bei AMNOG-Nutzenbewertungen
by: Dr. PH Andrej Rasch
Published: (2024-08-01)

AMNOG 2.0 für „besondere Therapiesituationen“
by: Peter Stegmaier
Published: (2024-08-01)

Die „Target Trial Emulation“ zu CAR-T im AMNOG
by: Janine Jakobs BS MS, et al.
Published: (2023-12-01)

Die neuen „Leitplanken“ im AMNOG-Prozess
by: Dr. PH Andrej Rasch
Published: (2023-08-01)

Kinderarzneimittel und Besonderheiten von pädiatrischen Studien im AMNOG
by: Dr. PH Andrej Rasch
Published: (2024-02-01)

Auswirkungen der neuen Dossieranforderungen
by: Dr. rer. nat. Maria Katharina Schweitzer, et al.
Published: (2023-06-01)

Das Verfahren der anwendungsbegleitenden Datenerhebung für die frühe Nutzenbewertung
by: Dr. rer. nat. Florian Jantschak, et al.
Published: (2025-08-01)

Die Festbetragsregelung im AMNOG-Markt – ein Blick aus der Praxis
by: Susann Lukat, et al.
Published: (2024-12-01)

Ein Plädoyer für die Möglichkeit vertraulicher Preise
by: Prof. Dr. Wolfgang Greiner, et al.
Published: (2024-08-01)

„Stärkerer Fokus auf die Methoden der Studiendurchführung“
by: Dr. med. Thomas Kaiser, et al.
Published: (2025-04-01)

Expenditure trends of orphan drugs in Serbia: 8-Year analysis of orphan drug market in Serbia
by: Pejčić Ana V., et al.
Published: (2016-01-01)

Public spending on orphan medicines: a review of the literature
by: Margit Gombocz, et al.
Published: (2020-12-01)

Current Situation, Trend, and Opportunity of Applying Blockchain to the Supply Chain of Orphan Drugs
by: LI Wenyan, et al.
Published: (2025-01-01)

Just Treatment of Orphans as Viewed by Quran Interpreters
by: Muhammad Moradi, et al.
Published: (2020-12-01)

Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases
by: V. Vanhoorne, et al.
Published: (2019-08-01)

Debates over orphan drug pricing: a meta-narrative literature review
by: Matthew S. Hanchard
Published: (2025-03-01)

Anxiety, Depression, Stress, and Decision-Making Among Orphans and Non-Orphans in Pakistan
by: Shafiq F, et al.
Published: (2020-03-01)

Änderungen der zweckmäßigen Vergleichstherapie
by: Dr. PH Andrej Rasch
Published: (2022-10-01)

Orphan diseases — rare but important!
by: article Editorial
Published: (2019-06-01)

Orphan diseases — rare but important!
by: article Editorial
Published: (2019-06-01)

Investigating the landscape of US orphan product approvals
by: Kathleen L. Miller, et al.
Published: (2018-10-01)

EMA approved orphan medicines since the implementation of the orphan legislation
by: Eveliina Hahl, et al.
Published: (2025-06-01)

SOCIO-CULTURAL ADAPTATION OF CHILDREN-ORPHANS BY LITERATURE
by: N. Yushkina
Published: (2018-03-01)

Regulatory Standards in Orphan Medicinal Product Designation in the EU
by: Stelios Tsigkos, et al.
Published: (2021-06-01)

Analysis of patient access to orphan drugs in Turkey
by: Güvenç Koçkaya, et al.
Published: (2021-02-01)

Protective behaviours among orphaned learners in a district of Gauteng province, South Africa
by: Thembi V. Simbeni, et al.
Published: (2025-03-01)

Physical activity and quality of life in adolescents and orphans
by: Lucija Maglica, et al.
Published: (2020-06-01)

Orphan diseases and associated problems
by: V. A. Shashel, et al.
Published: (2021-07-01)

Assessment of Psychological Status of Orphans in Orphanagesin Baghdad City
by: Saja H. Mohamed, et al.
Published: (2016-04-01)

Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01)

Practice of the Qualification and Recognition for Orphan Drugs in the World and its Inspiration
by: ZHU Xiaohong, et al.
Published: (2022-07-01)

Development of orphan drugs for rare diseases
by: Han-Wook Yoo
Published: (2024-07-01)

Trends in orphan medicinal products approvals in the European Union between 2010–2022
by: Luísa Bouwman, et al.
Published: (2024-02-01)

Visual Research of Global Orphan Drug from a Bibliometric Perspective
by: Wen X, et al.
Published: (2025-05-01)

Machbarkeit und Praktikabilität der anwendungsbegleitenden Datenerhebung (AbD) - Erfahrungen, Analysen und Weiterentwicklungsvorschläge
by: Dr. rer. nat. Matthias Wilken, et al.
Published: (2024-02-01)

Basic Data, Concerning the Rearing of an Orphan Foal
by: Flavia Bochiș, et al.
Published: (2023-09-01)

Features of intellectual property protection mechanisms on the example of orphan drugs circulation
by: D. S. Yurochkin, et al.
Published: (2022-01-01)

Zunahme von Infektionen der oberen Atemwege nach der Covid-19-Pandemie
by: Prof. Dr. rer. med. habil. Karel Kostev MA, et al.
Published: (2024-02-01)